CDTX - Cidara/Mundipharma rezafungin gets promising innovative medicine status in UK

Mundipharma and Cidara Therapeutics (NASDAQ:CDTX) said that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. granted rezafungin Promising Innovative Medicine (PIM) designation to treat invasive candidiasis. Invasive candidiasis is an infection caused by a yeast (a type of fungus) called Candida. It is a serious infection that can affect the blood, heart, brain, bones, and other parts of the body. The company said the PIM designation is a pre-requisite for application to the UK’s Early Access to Medicines Scheme (EAMS), which gives patients with life threatening or seriously debilitating conditions access to medicines that do not have a marketing authorization. Mundipharma and Cidara plan to submit an EAMS application for rezafungin in Q3 2022. Cidara has collaborated with Mundipharma who has commercial rights to rezafungin outside the U.S. and Japan. CDTX +5.80% pre-market to $0.73

For further details see:

Cidara/Mundipharma rezafungin gets promising innovative medicine status in UK